Bob Hoffman is co-founder of Khartis Therapeutics and serves as the Chief Executive Officer.  Bob previously served as VP of Chemistry at XinThera Inc. leading the discovery of the PARP1 selective inhibitor GS-0201 acquired by Gilead in 2023 along with a CNS available PARP1 selective and MK2 drug candidates.  Prior to XinThera, Bob had a highly decorated career at Pfizer spanning 32 years discovering clinical canidates in CNS, virololgy and oncology therapeutic areas. Highlights of his time at Pfizer include being a key contributor and inventor to the discovery of Lorbrena®, a CNS-penetrant Alk inhibitor, inventor of the CDK2/4/6 inhibitor ebvaciclib, inventor and project co-lead for the CDK2 selective inhibitor tegtociclib, and inventor of the SARS-CoV-2 Mpro inhibitor lufotrelvir.  Bob is an author of over 60 patents and papers, a recipient of the 1999 ACS Technical Achievements in Organic Chemistry award and the 2021 ACS Heroes of Chemistry award.